RO4 Cost-effectiveness analysis of rFVIIIFc, PEGylated rFVIII, and emicizumab for the prophylactic treatment of severe hemophilia A patients without inhibitors in the United States

Li, N., Bullement, A. orcid.org/0000-0001-7091-0972, McMordie, S. et al. (2 more authors) (2019) RO4 Cost-effectiveness analysis of rFVIIIFc, PEGylated rFVIII, and emicizumab for the prophylactic treatment of severe hemophilia A patients without inhibitors in the United States. In: Value in Health. ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, 18-22 May 2019, New Orleans, LA, USA. Elsevier , S389.

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2019 The Authors. For re-use permissions please contact the authors.
Dates:
  • Published (online): 24 June 2019
  • Published: 18 May 2019
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield)
Depositing User: Symplectic Sheffield
Date Deposited: 04 Feb 2021 11:13
Last Modified: 04 Feb 2021 16:34
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/j.jval.2019.04.1898

Download

Share / Export

Statistics